HADEEL H. SAMARKANDI

Board-certified oncology pharmacy leader with over a decade of progressive leadership in oncology pharmacy. Extensive experience directing pharmacy services, building residency programs, and leading national initiatives in CAR-T and stem cell therapy. Proven record of strategic leadership, cost optimization, and multidisciplinary collaboration, with recognition as a national and international speaker and researcher. Committed to advancing institutional performance and patient outcomes at the Director/Head level.

• - Coordinator, Plasma Derivative Pharmaceutical Committee (2024 – Present)
• - Member, Formulary & Therapeutic Subcommittee (2023 – Present)
• - Member, Antibiotic Utilization Subcommittee (2023 – Present)
• - Member, CAR-T Cell Oversight Committee (2021 – Present)
• - Member, SCT & CT Committee (2021 – Present)
• - Member, Chemotherapeutics Subcommittee (2018 – Present)

• - Samarkandi H, et al. Excellent Outcomes of HLA Matched Related Donor Transplant for Severe Sickle Cell Disease. 2023.
• - Samarkandi H, et al. Superior Outcome of Bone Marrow Transplantation in Severe Aplastic Anemia. 2023.
• - Samarkandi H, et al. Role of Anti-CD38 Monoclonal Antibodies in Adult Hematological Diseases. 2023.
• - Samarkandi H, et al. Outcome of CAR-T Therapy in Relapsed/Refractory NHL: Real World Data. 2023.
• - Samarkandi H, et al. Cancer Management in Saudi Arabia: National Recommendations. 2021. Full list available upon request.
• - Speaker, MEA COE 2024: Role of Clinical Pharmacist in Hematology Malignancies
• - Speaker, Arab International Pharmacy Congress 2024: Navigating CAR-T Therapy
• - Invited Lecturer, SFDA 2023: Practical Considerations in CAR-T Therapy
• - Speaker, SSCP International Conference 2022
• - Speaker, SOPA and SOHO Meetings (2019–2024)